RecruitingPhase 2NCT05745857

Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas

A Phase 2 Intervention Study: Detection of Early Esophageal Neoplastic Lesions by Quantified Fluorescence Molecular Endoscopy Using Oral and Topical Administration of Bevacizumab-800CW and Cetuximab-800CW

Sponsor

University Medical Center Groningen

Enrollment

25 participants

Start Date

Sep 15, 2023

Study Type

INTERVENTIONAL

Conditions

Esophageal Adenocarcinoma Barrett's Esophagus Without Dysplasia Barrett Oesophagitis With Dysplasia

Summary

Previous studies have confirmed the great potential of quantitative fluorescence molecular endoscopy (qFME) when looking at additional lesion detection initially missed by high-definition white light endoscopy (HD-WLE) for surveillance of Barrett's esophagus.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Avastin, a drug called Erbitux, and others for people with barrett oesophagitis with dysplasia, barrett's esophagus without dysplasia, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAvastin

Orally administered

DRUGErbitux

Orally administered

DEVICEFluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy

Fluorescent endoscope fiber and spectroscopy probe will be inserted through the working channel of the normal clinical therapeutic endoscope

Locations(1)

University Medical Center Groningen

Groningen, Provincie Groningen, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05745857

Related Trials

Postoperative Hypoxemia Increases the Risk of Anastomotic Leak After Radical Esophagectomy

NCT073099916 locations

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

NCT0728418610 locations

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

NCT0739289271 locations

Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples

NCT060718455 locations

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

NCT075445893 locations